Abbott account plan
Healthcare and life technologies
At a glance
Abbott is a diversified healthcare group in medical devices, diagnostics, nutrition and branded generics: $44,328 million FY2025 net sales, 122,000 staff.
Abbott Laboratories develops, manufactures and sells medical devices, diagnostic systems and tests, pediatric and adult nutrition, and branded generic medicines to hospitals, laboratories, pharmacies, retailers, governments and consumers in more than 160 countries. FY2025 net sales were $44,328 million (+5.7%), with operating earnings of $8,053 million and net earnings of $6,524 million; international markets were 61% of sales and emerging markets 37%. It had about 115,000 employees at December 31, 2025 (69% outside the U.S.) and cited 122,000 colleagues in its Q2 2026 release. Abbott is incorporated in Illinois and led by Chairman and CEO Robert B. Ford; it closed the acquisition of Exact Sciences on March 23, 2026, entering cancer diagnostics.
Business units
Medical Devices
about 48% of FY2025 sales ($21,387 million)Diabetes Care (FreeStyle Libre CGM, $7,998 million in 2025), Electrophysiology, Rhythm Management, Structural Heart, Heart Failure, Vascular and Neuromodulation. Sales grew 11.9% excluding FX in 2025 with a 33.7% segment operating margin, and 8.0% excluding FX in the first half of 2026. Led by Lisa D. Earnhardt, Executive Vice President and Group President.
Diagnostic Products
about 20% of FY2025 sales ($8,937 million)Core Laboratory (Alinity, ARCHITECT), Rapid and Molecular (combined from 2026) and, since March 23, 2026, Cancer Diagnostics from Exact Sciences (Cologuard, Oncotype DX, Cancerguard). Sales fell 4.5% excluding FX in 2025 on lower COVID-19 testing and China volume-based procurement; first-half 2026 sales were $5,272 million, +22.4%, with the acquisition.
Nutritional Products
about 19% of FY2025 sales ($8,451 million)Pediatric (Similac, PediaSure, Pedialyte, EleCare) and adult nutrition (Ensure, Glucerna, enteral feeding). Sales were +1.1% excluding FX in 2025 and -5.6% in the first half of 2026 on lower U.S. volumes; targeted price cuts in Q4 2025 are lifting Ensure volumes. Led, with Established Pharmaceuticals, by Daniel Salvadori.
Established Pharmaceutical Products
about 12.5% of FY2025 sales ($5,536 million)Branded generics sold only outside the U.S. in emerging markets, across gastroenterology, women's health, cardiometabolic, pain/CNS, respiratory and vaccines, plus biosimilars. Sales grew 7.4% excluding FX in 2025 and 8.9% in the first half of 2026, led by Key Emerging Markets in Latin America and Asia Pacific.
Strategic priorities
- Sustained 7% top-line growth
- Robert Ford said "7% is still the right target" for sales growth on the Q2 2026 call: Nutrition 2%-4%, Diagnostics 7%-8%, EPD 7%-9% and MedTech 8%-10%, aiming for high single-digit sales and double-digit EPS growth.
- Expand continuous glucose monitoring
- Abbott sees 75 to 80 million people who could realistically use a CGM versus 15 million today; U.S. type 2 non-insulin coverage would open about 10 million Medicare beneficiaries. Libre Duo, a dual glucose-ketone sensor, got its CE Mark in May 2026.
- Build cancer diagnostics
- After closing Exact Sciences, Abbott aims to cover screening, therapy selection and MRD testing; Cancer Diagnostics grew 13% in Q2 2026 with mid-teens Cologuard growth, and care gap programs with health systems ramp in the second half.
- Win in electrophysiology
- Volt PFA moves to full U.S. release in Q3 2026, with Abbott "selling the entire procedure" (PFA catheters, mapping, ICE, introducers) and PFA iterations planned through 2029; Amulet 360 may be approved by year-end.
- Restore Nutrition and Structural Heart growth
- Q4 2025 price cuts and launches (high-protein low-sugar Ensure, a collagen protein shake, a whole-milk infant formula) target Nutrition volumes; in U.S. mitral, Abbott made personnel changes to fix commercial execution.
- R&D pipeline
- R&D is targeted at about 7% of sales in 2026. Trials starting include balloon-expandable TAVR, leadless conduction system pacing, a Cephea mitral replacement valve, peripheral IVL and a wearable lactate sensor, targeting contributions in 2029-2030.
Latest results
In Q2 2026 (quarter to June 30) net sales were $12,593 million, +13.0% reported and +4.8% on a comparable basis that includes Exact Sciences in both years. Medical Devices grew 8.4% and Established Pharmaceuticals 8.7% comparable, Diagnostics 2.9% (Cancer Diagnostics +13.3%, Rapid/Molecular -8.0%) and Nutrition fell 3.6%. GAAP net earnings fell to $928 million ($0.53 diluted EPS) from $1,779 million on higher amortization, integration costs, legal reserves and interest; adjusted diluted EPS was $1.31 vs $1.26. Full-year 2026 guidance: comparable sales growth of 6.5% to 7.5% reaffirmed and adjusted diluted EPS raised to $5.45-$5.60, with Q3 adjusted EPS of $1.38-$1.46.
Investments and deals
- Exact Sciences acquisition
- Completed March 23, 2026 for about $20.6 billion ($105 per share in cash), funded mainly by $20.0 billion of long-term debt; Abbott also repaid nearly all of about $2.8 billion of assumed debt. Exact Sciences had $3.247 billion of 2025 sales and is expected to add about $3 billion in 2026.
- Fifth CGM sensor plant
- Abbott is in the final stages of planning a fifth sensor plant, which Ford said would "probably be a billion dollar investment", as its fourth plant nears capacity.
- Capex and R&D
- FY2025 capex was $2.2 billion and R&D $2.9 billion; Q2 2026 R&D rose 22.9% to $892 million.
- Shareholder returns
- Abbott returned $2.1 billion to shareholders in Q2 2026; the quarterly dividend is $0.63 per share, raised for 54 consecutive years, and $5.6 billion of buyback authorisation remained at June 30, 2026.
Challenges and risks
- Higher debt after Exact Sciences
- Net interest expense rose $249 million to $299 million in Q2 2026 and cash fell from $8.5 billion to $5.1 billion in the first half; the 10-K flagged the extra borrowing as a risk to flexibility and credit ratings.
- China and COVID-19 testing in Diagnostics
- Volume-based procurement drove China Core Lab declines of 15% to 30% a quarter in 2025, and COVID-19 testing sales fell from $1.6 billion in 2023 to $297 million in 2025; Diagnostics operating margin dropped from 24.4% in 2023 to 19.5% in 2025.
- Infant formula litigation
- 1,760 preterm infant formula (NEC) lawsuits were pending at January 31, 2026; the Missouri Court of Appeals affirmed a $495 million verdict in May 2026, and a DOJ criminal investigation into powdered infant formula manufacturing is ongoing.
- Nutrition volumes
- Nutrition sales fell 5.6% in the first half of 2026 on lower adult and U.S. pediatric volumes, with U.S. Pediatric down 11.9%.
- Tariffs, regulation and supply chain
- The 10-K lists supply chain disruption, cybersecurity, FDA and EU MDR/IVDR regulation, cost containment, tariffs, geopolitics and FX among its main risks.
What leadership says
“We expect this momentum to continue and drive accelerating sales and earnings growth in the second half of the year.”
“7% is still the right target”
“I am never going to make a long-term strategic decision based on near-term challenges.”
Where a supplier can help
- Manufacturing capacity for CGM
- The planned fifth sensor plant, a roughly billion-dollar investment, opens needs for equipment, automation, construction and supply chain partners.
- Integrating Exact Sciences
- Integration of a $20.6 billion acquisition, with integration expenses already weighing on SG&A, creates work in systems, finance, data and commercial operations alignment.
- Commercial execution in cancer screening
- Care gap programs tied to health systems' HEDIS and star ratings and the Cologuard rescreen funnel are growth levers where patient engagement, analytics and outreach tools can help.
- Cost and margin programmes
- With higher interest costs and margin initiatives behind the gross margin gains, suppliers offering procurement, logistics or operating-cost savings align with management's focus.
- Regulatory and quality compliance
- EU MDR/IVDR transitions and the infant formula manufacturing scrutiny point to demand for quality, compliance and manufacturing-traceability solutions.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Abbott?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Form 10-K for the fiscal year ended December 31, 2025
- Abbott Laboratories is a diversified healthcare group (incorporated 1900, Illinois) with four reportable segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Medical Devices; about 115,000 employees at December 31, 2025, 69% outside the U.S.
- FY2025 net sales were $44,328 million (+5.7% reported; $41,950 million in 2024); operating earnings $8,053 million; net earnings $6,524 million; diluted EPS $3.72. International markets were 61% of sales and emerging markets 37%.
- Medical Devices is the engine: $21,387 million of sales, +11.9% excluding FX, segment operating margin 33.7%. Diabetes Care (FreeStyle Libre CGM) reached $7,998 million; CGM sales totaled $7.6 billion, +17.4% excluding FX.
- Diagnostics sales fell 4.5% excluding FX to $8,937 million (COVID-19 testing down to $297 million group-wide; China volume-based procurement); its operating margin dropped from 24.4% in 2023 to 19.5%.
- Nutrition was flat (+1.1% excluding FX, $8,451 million) on lower U.S. volumes; Established Pharmaceuticals grew 7.4% excluding FX ($5,536 million), led by Key Emerging Markets (+9.5%).
- On November 19, 2025 Abbott agreed to buy Exact Sciences for $105 per share in cash (about $21 billion equity value, $23 billion enterprise value) to enter cancer diagnostics, to be funded with about $20 billion of borrowings.
- Group operating margin rose to 18.2% (16.3% in 2024) and gross margin to 52.6% on margin-improvement initiatives, despite tariffs and FX; R&D was $2.9 billion, targeted at about 7% of sales in 2026; capex $2.2 billion.
- Main risks: supply chain, cybersecurity, regulation and cost containment, the extra debt for Exact Sciences, tariffs and geopolitics, FX, and product-liability litigation such as the preterm infant formula (NEC) lawsuits (1,760 pending at January 31, 2026).
- Form 10-Q for the quarter ended June 30, 2026
- Q2 2026 (quarter to June 30) net sales were $12,593 million, +13.0% reported and +12.2% excluding FX, driven by the Exact Sciences acquisition (closed March 23, 2026) and high single-digit growth in Medical Devices and Established Pharmaceuticals.
- First-half net sales $23,757 million (+8.2% excluding FX); Exact Sciences contributed about $1.0 billion, reported as Cancer Diagnostics within Diagnostic Products.
- Q2 segment sales: Medical Devices $5,853 million (+7.9% excl. FX), Diagnostics $3,092 million (+41.3%), Nutrition $2,144 million (-3.6%), Established Pharmaceuticals $1,499 million (+8.7%).
- Q2 net earnings fell to $928 million ($0.53 diluted EPS) from $1,779 million, on higher amortization, Exact Sciences integration costs, legal reserves and interest; interest expense, net rose $249 million to $299 million.
- Exact Sciences cost about $20.6 billion, funded mainly by $20.0 billion of new long-term debt; Abbott also repaid nearly all of $2.8 billion of assumed debt. Goodwill rose to $35.2 billion.
- CGM sales were $4.1 billion in the first half (+8.6% excl. FX); Libre Duo dual glucose-ketone sensor got its CE Mark in May 2026.
- Cash fell from $8.5 billion to $5.1 billion; long-term debt rated A+ (S&P) and Aa3 (Moody's) at June 30. Abbott repurchased $1.0 billion of shares in the half.
- Litigation: in May 2026 the Missouri Court of Appeals affirmed the $495 million Gill verdict in the preterm formula (NEC) litigation; Abbott sought Supreme Court of Missouri review.
- Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance (Exhibit 99.1)
- Q2 2026 sales $12,593 million: +13.0% reported, +4.8% on a comparable basis (which includes Exact Sciences in both years and excludes FX and Structural Heart compensation payments).
- GAAP diluted EPS $0.53; adjusted diluted EPS $1.31 (vs $1.26), excluding $0.78 per share of specified items (amortization, acquisition charges, legal reserves, impairments).
- Full-year 2026 guidance: comparable sales growth 6.5% to 7.5% reaffirmed; adjusted diluted EPS raised to $5.45-$5.60 (from $5.38-$5.58); Q3 adjusted EPS $1.38-$1.46.
- Comparable growth by segment in Q2: Medical Devices +8.4%, Established Pharmaceuticals +8.7%, Diagnostics +2.9% (Cancer Diagnostics +13.3%, Core Lab +3.2%, Rapid/Molecular -8.0%), Nutrition -3.6%.
- CGM sales grew 9.5% comparable; Electrophysiology +13.4%; Structural Heart +5.7% comparable but -9.8% reported in the U.S.
- Pipeline: TECTONIC coronary IVL trial enrollment completed, Libre Duo CE Mark, FDA submission for the Amulet 360 LAA device; the American Cancer Society reaffirmed Cologuard as a preferred colorectal screening option.
- Abbott returned $2.1 billion to shareholders in the quarter; dividend increased for 54 consecutive years; 122,000 colleagues.
- CEO Robert B. Ford: "We expect this momentum to continue and drive accelerating sales and earnings growth in the second half of the year."
- Abbott Q2 2026 earnings call transcript
- Robert Ford framed Q2 2026 comparable growth of 4.8% as an acceleration, reaffirmed 6.5%-7.5% comparable sales growth and raised adjusted EPS guidance to $5.45-$5.60.
- About 80% of the expected second-half lift comes from four businesses: Nutrition, Electrophysiology, Core Lab and Cancer Diagnostics.
- He sees no slowdown in U.S. procedure volumes: Medicare, not Medicaid, drives device procedures; U.S. Core Lab grew 7.5% and U.S. hospital lab instruments and reagents 13%.
- CGM: 75-80 million people could realistically use a CGM vs 15 million today; U.S. type 2 non-insulin coverage would open about 10 million Medicare beneficiaries; a fifth sensor plant, likely about a $1 billion investment, is being planned.
- Cancer Diagnostics grew 13% with mid-teens Cologuard growth; the deal model assumed mid-teens 2026 growth, with care gap programs ramping in the second half.
- Electrophysiology: Volt PFA moving to full U.S. release in Q3, EP up 20% in Europe; Amulet 360 approval possibly by year-end.
- Long-term frame: 7% top-line growth is sustainable - Nutrition 2%-4%, Diagnostics 7%-8%, EPD 7%-9%, MedTech 8%-10%.
- CFO Philip Boudreau: adjusted gross margin 58.0% (+100 basis points), Q3 adjusted EPS guidance $1.38-$1.46.
- Abbott Q1 2026 earnings call transcript
- Q1 2026 call (April 16, 2026): adjusted EPS $1.15 (+6%), comparable sales growth 3.7%; Exact Sciences closed March 23, 2026 and is expected to add about $3 billion of 2026 sales.
- Adjusted EPS guidance midpoint cut from $5.68 to $5.48, reflecting $0.20 of Exact Sciences dilution; full-year comparable sales growth guidance 6.5% to 7.5%.
- Electrophysiology grew 13% with two PFA catheter launches (Volt in the U.S., TactiFlex Duo in Europe); Abbott sees the EP market at mid- to high-teens growth and aims to beat it.
- CGM sales of $2 billion grew 7.5%, held back by an international tender delay; Ford sees 70-80 million potential CGM users and about 10 million people gaining coverage under U.S. type 2 non-insulin reimbursement.
- Exact Sciences runs standalone under Jake Orville, reporting to Ford; about 50 million Americans are not up to date with colorectal screening and 25% of Cologuard tests are rescreens.
- Nutrition: targeted price cuts in Q4 2025 are starting to lift volume; portfolio is reviewed with the board at least yearly, but no long-term decision on near-term challenges.
- China Core Lab was flat in Q1 after 15%-30% quarterly declines; U.S. Core Lab grows high single digits with 90%+ contract renewals.
Questions about Abbott
What does Abbott do?
Abbott makes and sells medical devices (including FreeStyle Libre CGM), diagnostic systems and tests, pediatric and adult nutrition, and branded generic medicines in more than 160 countries.
What is Abbott's revenue?
FY2025 net sales were $44,328 million, up 5.7%, with net earnings of $6,524 million. Q2 2026 sales were $12,593 million, and 2026 guidance is 6.5% to 7.5% comparable sales growth.
How many employees does Abbott have?
About 115,000 at December 31, 2025, 69% outside the U.S.; the Q2 2026 release cited 122,000 colleagues after the Exact Sciences acquisition.
Who leads Abbott?
Robert B. Ford is Chairman and Chief Executive Officer; Philip P. Boudreau is EVP Finance and CFO.
What is Abbott's strategy?
Abbott targets about 7% top-line growth, led by CGM expansion, electrophysiology, cancer diagnostics from Exact Sciences and a recovery in Nutrition, with R&D at about 7% of sales.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)